AUROBAC THERAPEUTICS
Tackling bacterial infections, antimicrobial resistance, and their consequences in acute care settings.
31 employees · est. 2022 · Lyon, France
BioVersys AG
Leadership in overcoming the antibiotic resistance crisis.
27 employees · est. 2010 · Basel, Switzerland
BioVersys AG is the older company (2022 vs 2010).
Side-by-Side Comparison
| Metric | AUROBAC THERAPEUTICS | BioVersys AG |
|---|---|---|
| Founded | ||
| Founded | 2022 | 2010 older |
| Headquarters | ||
| Headquarters | Lyon, France | Basel, Switzerland |
| Employees | ||
| Employees | 31 | 27 |
| Industry | ||
| Industry | Biopharma, Health Care, Manufacturing | Biotechnology, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Seed | Series C |
| Total Funding | ||
| Total Funding | Not tracked yet | $103.88M |
| Funding Rounds | ||
| Funding Rounds | Not tracked yet | 14 |
| Services | ||
| Services | Research & Development of Precision Medicines, Clinical Trials and Development, Innovative Diagnostic Strategies, Business Development and Partnering | Not tracked yet |
| Target Customers | ||
| Target Customers | Healthcare Providers, Hospitals, Pharmaceutical Partners, Medical Research Institutions | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Biopharmaceuticals, Antimicrobial Resistance, Precision Medicine, Hospital-Acquired Infections, Ventilator-Associated Pneumonia, Sepsis Treatment, R&D Strategy, Life Sciences Innovation, Acute Care Settings, Joint Venture, Pathogen-Targeted Programs, Precision Medicines Development, Bacterial Infection Combat, Healthcare Innovation | Pharmaceuticals, Antimicrobial Resistance, Drug Development, Microbiome Modulation, Small Molecules, Clinical Stage, Swiss Company, Research And Development, Nosocomial Infections, Acinetobacter Baumannii, Tuberculosis, Collaboration With GlaxoSmithKline, University Consortium, TechPark Basel |
| Website | ||
| Website | aurobac-tx.com | bioversys.com |
About AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS is a promising player in the biopharmaceutical field, founded in 2022 by three industry giants: Boehringer Ingelheim, Evotec, and bioMérieux. With a clear mission to battle bacterial infections and Antimicrobial Resistance (AMR), it aims to make a significant impact in acute car...
About BioVersys AG
BioVersys AG is a privately-owned clinical stage Swiss pharmaceutical company founded in 2008. It focuses on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. The company's award-winni...
We will tell you when either one moves
BounceWatch watches AUROBAC THERAPEUTICS and BioVersys AG for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at AUROBAC THERAPEUTICS and BioVersys AG — by email.
Frequently Asked Questions
Compare AUROBAC THERAPEUTICS with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at AUROBAC THERAPEUTICS on 26 Nov 2025, and BioVersys AG on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.